News Headlines

  1. Harbour Biomed Enters Into Global Strategic Collaboration And License Agreement With Bristol Myers Squibb To Discover And Develop Next-Generation Multi-Specific Antibodies 12/16/2025

    Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies.

  2. Asimov Launches CHO Edge Rapid Pools To Bridge Biologics Discovery And CMC With Predictive Stable Expression 12/16/2025

    Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of CHO Edge Rapid Pools, a high-throughput stable CHO expression system that brings CMC-grade performance and assurance to biologics discovery teams.

  3. PharmaLogic Announces Successful Supply Of First Cohort Dosing For Ratio Therapeutics' Phase 1/2 Study Of A Novel FAP-Targeted Radiopharmaceutical In Late-Stage Aggressive Sarcomas 12/16/2025

    PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, announced today that it has successfully supplied the first cohort dosing of Ratio Therapeutics' investigational FAP-targeted radiopharmaceutical, [Ac-225]-RTX-2358, for the ATLAS trial.

  4. INCOG BioPharma Announces $200M Expansion, Growing The Team To Nearly 1,000 Employees 12/16/2025

    INCOG BioPharma Services, a leading contract development and manufacturing organization (CDMO), today announced another major expansion with an investment of approximately $200 million in its manufacturing facility in Fishers, Indiana.

  5. LVV Turbo: uBriGene's New GMP Lentiviral Vector Platform With UltraCell Integration 12/16/2025

    uBriGene Biosciences, a leading global lentivirus CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, today announced the official rebranding of its GMP lentiviral vector manufacturing platform to LVV Turbo, a high-performance system designed to deliver exceptional productivity, superior downstream yields, and a markedly lower cost of LVV manufacturing, enabling faster and more efficient vector development.

  6. Alcami Expands Drug Product Manufacturing Capacity To Meet Growing Demand 12/16/2025

    Alcami Corporation, a leading U.S. based contract development and manufacturing organization (CDMO), is proud to announce the GMP readiness of a third sterile fill-finish line at its Research Triangle Park, NC campus.

  7. RoslinCT And Ayrmid Ltd. Announce Expansion Of Strategic Partnership To Manufacture Omisirge (Omidubicel-onlv) For Second FDA-Approved Indication In Severe Aplastic Anemia (SAA) 12/16/2025

    Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge (omidubicel-onlv).

  8. Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform 12/15/2025

    Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform.

  9. PharmAla Biotech Australia Contracts With UK-based CDMO For Manufacture Of ALA-002 Drug Substance 12/15/2025

    PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that its wholly-owned subsidiary, PharmAla Biotech Australia, has contracted with a UK-based CDMO to execute manufacture of its ALA-002 drug substance.

  10. Viva Biotech's Invested And Incubated Company, Arthrosi, Has Entered Into An Acquisition Agreement With Sobi For A Total Transaction Value Of Up To US$1.5B. 12/15/2025

    Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings.